On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.

In addition to the shares sold in the initial public offering, Odyssey announced a concurrent sale of 1,388,889 shares of common stock to an affiliate of TPG Life Sciences Innovations, at the initial public offering price of $18.00 per share, in a private placement. The gross proceeds to Odyssey from the initial public offering and a concurrent private placement are expected to be approximately $304 million.

The Wilson Sonsini team that advised Odyssey on patent matters related to the transaction includes Michael Hostetler, Deborah Smith, Derrick Rowe, Uale Taotafa, U.P. Peter Eng, Victoria Cheng, Matt Wheeler, Jim Malecha, Sarah Cohen, and Katherine Forbes.

For more information, please see Odyssey’s news release.